{"id":56855,"date":"2024-02-27T17:10:31","date_gmt":"2024-02-27T17:10:31","guid":{"rendered":"https:\/\/medsname.com\/dulata\/"},"modified":"2026-04-30T10:24:34","modified_gmt":"2026-04-30T10:24:34","slug":"dulata","status":"publish","type":"product","link":"https:\/\/medsbase.com\/nl\/dulata\/","title":{"rendered":"Dulata"},"content":{"rendered":"

<\/p>\n

\n

\u26a1 Snel antwoord<\/h3>\n

Dulata (Duloxetine 20 \/ 30 \/ 40 \/ 60 mg) is a serotonin-noradrenaline reuptake inhibitor used for major depression, generalised anxiety, diabetic peripheral neuropathy, fibromyalgia, and chronic musculoskeletal pain. Particularly useful when depression is paired with chronic pain.<\/p>\n<\/div>\n

\nWat u krijgt bij MedsBase:<\/strong> WHO-GMP gecertificeerde fabrikant \u00b7 Discrete verpakking \u00b7 Wereldwijde verzending \u00b7 1.400+ geverifieerde klantbeoordelingen<\/a>\n<\/div>\n

\ud83d\udce6 Elke bestelling is gedekt door onze Reshipment Assurance Policy<\/strong><\/a> \u2014 als uw pakket niet binnen 20 werkdagen arriveert, sturen wij het opnieuw.<\/p>\n

Waarom bestellen bij MedsBase<\/h3>\n

Dulata at MedsBase is supplied directly from a WHO-GMP certified manufacturer in plain, discreet packaging. Every order is covered by our Reshipment Assurance Policy<\/a> \u2014 20 werkdagen levertermijn of wij sturen kosteloos opnieuw \u2014 en komt in aanmerking voor ons klantenloyaliteitsprogramma<\/a>. Wereldwijde verzending is beschikbaar naar de meeste bestemmingen.<\/p>\n

What Dulata is and how it works<\/h2>\n

Dulata is a 20 \/ 30 \/ 40 \/ 60 mg duloxetine delayed-release capsule supplied by Sun Pharma. Duloxetine is a balanced inhibitor of both serotonin (5-HT) and noradrenaline (NA) reuptake at their presynaptic transporters. The dual-action profile is what makes it effective for both mood and pain.<\/p>\n

The therapeutic effect on mood and anxiety builds over 4\u20136 weeks; analgesic effects on neuropathic and musculoskeletal pain often appear within 1\u20132 weeks at the same dose.<\/p>\n

Indicaties en dosering<\/h2>\n\n\n\n\n\n\n\n\n\n\n
Indicatie<\/th>\nStartdosering<\/th>\nStreefdosering<\/th>\nMaximaal<\/th>\n<\/tr>\n<\/thead>\n
Depressie<\/td>\n30 mg OD \u00d7 1 wk<\/td>\n60 mg OD<\/td>\n120 mg (split BID)<\/td>\n<\/tr>\n
Generalised anxiety<\/td>\n30 mg OD \u00d7 1 wk<\/td>\n60 mg OD<\/td>\n120 mg<\/td>\n<\/tr>\n
Diabetic peripheral neuropathy<\/td>\n30 mg OD \u00d7 1 wk<\/td>\n60 mg OD<\/td>\n60 mg<\/td>\n<\/tr>\n
Fibromyalgia<\/td>\n30 mg OD \u00d7 1 wk<\/td>\n60 mg OD<\/td>\n60 mg<\/td>\n<\/tr>\n
Chronic musculoskeletal pain<\/td>\n30 mg OD \u00d7 1 wk<\/td>\n60 mg OD<\/td>\n60 mg<\/td>\n<\/tr>\n
Stress urinary incontinence (off-label, EU)<\/td>\n20 mg BID<\/td>\n40 mg BID<\/td>\n40 mg BID<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

Belangrijke veiligheidsoverwegingen<\/h2>\n
\nHepatic \u2014 avoid in significant alcohol use or hepatic impairment<\/strong><\/p>\n

Duloxetine has a baseline hepatotoxicity signal that becomes clinically important in patients with significant alcohol intake (\u22653 drinks\/day) or chronic liver disease. Avoid in any clinically significant hepatic impairment.<\/strong> Check baseline LFTs in older adults and patients on multiple hepatically-cleared drugs.<\/p>\n<\/div>\n

\nBloeddruk<\/strong><\/p>\n

Duloxetine produces a small but real rise in BP \u2014 average +2\u20133 mmHg systolic at therapeutic doses. Less than venlafaxine, but enough to matter in poorly-controlled hypertension. Check BP at baseline, at 2 weeks, and at every dose increase.<\/p>\n<\/div>\n

\nDiscontinuation syndrome<\/strong><\/p>\n

Duloxetine has a short elimination half-life (12 hours) \u2014 abrupt cessation produces dizziness, paraesthesia (“zaps”), nausea, headache, and dysphoria within 24\u201372 hours. Always taper over at least 2\u20134 weeks. The lowest available capsule strength (20 mg or 30 mg, depending on market) sets the floor of the taper \u2014 beading the capsule contents is sometimes used clinically for the final step.<\/p>\n<\/div>\n

\nZwarte waarschuwing voor su\u00efcidaliteit (onder 25)<\/strong><\/p>\n

Alle antidepressiva dragen een FDA zwarte waarschuwing voor verhoogde su\u00efcidale gedachten bij pati\u00ebnten onder de 25.<\/p>\n<\/div>\n

Veelvoorkomende bijwerkingen<\/h2>\n